Direct oral anticoagulants (DOAC s) have quickly become attractive alternatives to the long‐
standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for …

Anticoagulants are the mainstay for the prevention and treatment of thrombosis. However,
bleeding complications remain a primary concern. Recent advances in understanding the …

Reduction of lipoprotein uptake by macrophages and stimulation of cholesterol efflux are
two essential steps required for atherosclerotic plaque regression. We used the optimized …

Atherosclerosis is a systemic disease with different faces. Despite identical or similar
pathogenetic mechanisms, atherosclerotic lesions and their clinical manifestations vary in …

The formation of an obstructive thrombus within an artery remains a major cause of mortality
and morbidity worldwide. Despite effective inhibition of platelet function by modern …

Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …

Abstract Purpose Direct oral anticoagulants (DOACs) have been approved, for over a
decade, by both European and American medicine agencies, for treatment and prevention …

Atherosclerosis is a multifactorial vascular disease that develops in the course of a lifetime.
Numerous risk factors for atherosclerosis have been identified, mostly infiicting pro …

Aims/hypothesis Individuals with type 2 diabetes mellitus and subclinical inflammation have
stimulated coagulation, activated platelets and endothelial dysfunction. Recent studies with …

Introduction: The current approach of using only antiplatelet therapy for secondary
prevention leaves a substantial risk of recurrent cardiovascular complications and mortality …